A-005

About Alumis

Alumis is a clinical-stage biotech advancing a late-stage portfolio of precision oral therapies for immune-mediated diseases, leveraging a proprietary data analytics platform to de-risk development. The company's lead asset, envudeucitinib, has delivered strong Phase 3 data in plaque psoriasis, potentially positioning it as a best-in-class oral TYK2 inhibitor. With a seasoned leadership team and a $2.91B valuation, Alumis's strategy focuses on bringing its lead program to market while expanding into adjacent immunology indications to build a multi-product company.

Therapeutic Areas